A saga involving CureVac AG, one of Europe’s most promising biotechs, entered a new phase on 16 March when the European Commission offered to provide up to €80 million in financial support to help the company scale up development and production of a vaccine against the coronavirus 2019-nCoV, also known as SARS-CoV-2.
